about
Seasonal variation in vitamin D levels in psoriatic arthritis patients from different latitudes and its association with clinical outcomes.Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada StudyRisk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta-Analysis of Observational Studies.Utility of untimed single urine protein/creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus.Prevalence and associated factors of resting electrocardiogram abnormalities among systemic lupus erythematosus patients without cardiovascular disease.TNF polymorphisms in patients with Behçet disease: a meta-analysis.Top 10 recent developments in health-related quality of life in patients with systemic lupus erythematosus.Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus.Utility of Urinary Protein-Creatinine Ratio and Protein Content in a 24-Hour Urine Collection in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.Recent advances in the biologic therapy of lupus: the 10 most important areas to look for common pitfalls in clinical trials.The utility of lupus serology in predicting outcomes of renal transplantation in lupus patients: Systematic literature review and analysis of the Toronto lupus cohort.Prevalence and associated factors of low bone mass in adults with systemic lupus erythematosus.Predictors of Good Long-Term Renal Outcomes in Lupus Nephritis: Results from a Single Lupus Cohort.The assessment of disease activity in rheumatic diseases.Development and assessment of users' satisfaction with the systemic lupus erythematosus disease activity index 2000 responder index-50 website.Development, sensibility, and reliability of the Toronto Axial Spondyloarthritis Questionnaire in inflammatory bowel disease.GRAPPA Trainees Symposium 2012: a report from the GRAPPA 2012 annual meeting.Comparison of the Sensitivity to Change of the 36-Item Short Form Health Survey and the Lupus Quality of Life Measure Using Various Definitions of Minimum Clinically Important Differences in Patients With Active Systemic Lupus Erythematosus.Successful retreatment with infliximab in patients with prior severe infusion reactions.Long-delayed onset of chest wall pain defining a patient with SAPHO syndrome.Performance of Screening Tests for Cognitive Impairment in Systemic Lupus Erythematosus.Impact of pulmonary disease on patient-reported outcomes and patient-performed functional testing in systemic lupus erythematosus.Comparison of Spot Urine Protein to Creatinine Ratio to 24-Hour Proteinuria to Identify Important Change Over Time in Proteinuria in Lupus.Effect of complete or partial proteinuria recovery on long-term outcomes of lupus nephritis.Successful treatment of cardiac involvement in dermatomyositis with rituximab.What is the prevalence of cognitive impairment in lupus and which instruments are used to measure it? A systematic review and meta-analysis.A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index.Identification of a neutrophil-related gene expression signature that is enriched in adult systemic lupus erythematosus patients with active nephritis: Clinical/pathologic associations and etiologic mechanisms.How Do Patients with Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification CriteriaEfficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled studyImpact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studiesOral bisphosphonates in treatment of transient osteoporosisFamily history of lymphoma and risk for solid tumors in patients with Sjogren’s syndromeLongitudinal myelitis in patient with systemic lupus erythematosus, homozygous prothrombin G20210A and heterozygous MTHFR 677TSuccessful treatment of Sjogren's syndrome with rituximabCardiac sarcoidosis responding to monotherapy with infliximabResponse of deep cutaneous vasculitis to infliximabFatal streptococcal toxic shock syndrome in a patient with rheumatoid arthritis treated with etanerceptSystemic lupus erythematosus disease activity Index 2000 Responder Index 50: sensitivity to response at 6 and 12 monthsSystemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials
P50
Q30410018-3FFED695-0EC0-4EF6-BB8C-EED40D8C67AEQ33695128-1DF7E562-5070-4FB6-B169-F2A476D9872BQ35998182-97C8B818-8F05-4705-92F1-AE8118855556Q36203113-A4016B47-1C6A-464B-A9CC-B9A55AE8A650Q37635186-8A62B734-E044-4DFA-88CE-F6AEEA437244Q37752615-2C2DC9BE-161D-41C7-B373-7F07B0802E4AQ38157723-0ECC81D1-E654-4614-8089-4E905F9746C1Q38271939-8E234108-26A1-44DC-901F-A4F21F334DB1Q38682220-3359A9D9-FA79-4E81-9996-4B518B089A17Q38840646-21041DE0-6898-4630-A0C3-9285C9666D66Q38987798-737856F8-5A40-4298-B463-61B496BEE4B4Q39492537-18EA3FE1-9610-4BF4-A6DA-6FEE38F7A962Q41622314-F1A4E68D-BE11-4196-9869-8E50F3DAC53EQ42870918-3DE9653A-07D9-4C1C-8652-85C0F02360B9Q43492255-C0DEEFE1-2B6A-4406-90CB-7FC3CA56C665Q44389164-01953910-9837-4D40-B229-6564F7004867Q44970394-062BB6B4-F601-488E-A674-B798585BCB3FQ46160179-155518FE-1529-4F1E-B94D-D99497BB9D98Q46740925-8BB7C0A9-8891-4BC3-BA67-EB4E485FA507Q46822373-B55D12E3-35D2-4CB0-B35C-EDCEEFC924EAQ47631357-C01AD049-E561-41BB-B58F-CD1CAFE8D5EBQ47891248-306CB36A-38A2-478F-B275-7DBA9DB92633Q47941402-193D4C98-FB84-489F-AB3D-708C6E517D20Q50188662-85E48243-93EA-442A-A5C2-2B95CE44B4C9Q51728885-99CA5339-ABFC-421C-98A6-34DDF21B3561Q52344235-A49297F1-7460-45DA-8221-B02B65324A80Q52567202-F5AE3845-6B6E-4378-8A6B-24F0C8AE04FBQ55092867-7C82EBC0-8FFD-4E89-8910-6F5FE10E1745Q56967361-229AC4F3-8974-460C-8987-CEBD5B050B60Q57469182-A0C3561A-C05D-44FC-AFBE-3690E9283554Q60913872-46C97216-993A-4867-A4DA-9634FACFEB14Q61767506-FFCAA2EB-C873-4B11-A35C-8C58D83C2764Q61767512-CCE741BA-2469-4326-B350-5BFF0CEAA8B2Q61767514-BB89D554-9E69-455B-8848-39DBA2F6F79FQ61767517-4F61DD79-7F5A-45DC-97D2-A3F629CC853DQ80061625-DD735D65-9DA4-460A-9BFC-07EF590CBB78Q80379852-A246D4C9-EBEF-4744-B775-15200CD1D1F6Q81712901-660FA997-8569-4D90-84ED-64904D489A6FQ84425138-3B36D6CD-FF49-4D22-B8AF-AC274A28DDB8Q84874273-0A1E2A10-7148-4C3F-A960-CA98DAE98CA5
P50
description
researcher ORCID ID = 0000-0001-5177-2076
@en
wetenschapper
@nl
name
Zahi Touma
@ast
Zahi Touma
@en
Zahi Touma
@es
Zahi Touma
@nl
type
label
Zahi Touma
@ast
Zahi Touma
@en
Zahi Touma
@es
Zahi Touma
@nl
prefLabel
Zahi Touma
@ast
Zahi Touma
@en
Zahi Touma
@es
Zahi Touma
@nl
P31
P496
0000-0001-5177-2076